LASTACAFT 2.5 mg/mL
alcaftadine · SOLUTION/ DROPS · Allergan, Inc.
LASTACAFT is a solution/ drops containing alcaftadine at 2.5 mg/mL, taken ophthalmic. Manufactured by Allergan, Inc..
Key Facts
- Brand Name
- LASTACAFT
- Generic Name
- alcaftadine
- NDC Code (Product)
0023-4291- Manufacturer
- Allergan, Inc.
- Strength
- 2.5 mg/mL
- Dosage Form
- SOLUTION/ DROPS
- Route
- OPHTHALMIC
- Marketing Status
- Application #
- NDA022134
- Drug Class
- Histamine-1 Receptor Antagonist [EPC]
- Marketing Start
- 12/01/2021
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Full Prescribing Information
Indications & Usage
1 INDICATIONS AND USAGE LASTACAFT ® is an H 1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. LASTACAFT ® is an H 1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. ( 1 )
Dosage & Administration
2 DOSAGE AND ADMINISTRATION Instill one drop in each eye once daily. If more than 1 topical ophthalmic medicinal product is being used, each one should be administered at least 5 minutes apart. Instill one drop in each eye once daily. ( 2 )
Contraindications
4 CONTRAINDICATIONS LASTACAFT ® is contraindicated in patients with hypersensitivity to any component in the product. Hypersensitivity ( 4 )
Adverse Reactions
6 ADVERSE REACTIONS The most common ocular adverse reactions, occurring in less than 4% of eyes treated with LASTACAFT ® , were eye irritation, burning and/or stinging on instillation, eye redness, and eye pruritus. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-678-1605 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The most frequent ocular adverse reactions, occurring in less than 4% of eyes treated with LASTACAFT ® , were eye irritation, burning and/or stinging upon instillation, eye redness and eye pruritus. The most frequent non-ocular adverse reactions, occurring in less than 3% of subjects with eyes treated with LASTACAFT ® , were nasopharyngitis and headache. Some of these events were similar to the underlying disease being studied. 6. 2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of LASTA…
Frequently Asked Questions
What is LASTACAFT used for?
LASTACAFT contains alcaftadine. It is a solution/ drops taken ophthalmic. Consult your doctor for specific uses.
Is LASTACAFT a controlled substance?
LASTACAFT is not classified as a controlled substance by the DEA.
What is the generic name for LASTACAFT?
The generic name for LASTACAFT is alcaftadine. There are 3 other brand versions of alcaftadine.
What is the NDC code for LASTACAFT 2.5 mg/mL?
The NDC (National Drug Code) for LASTACAFT 2.5 mg/mL is 0023-4291, listed by Allergan, Inc..